STOCK TITAN

MacroGenics (MGNX) director converts 3,750 RSUs into common shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MACROGENICS INC director Jay Philip Siegel exercised restricted stock units into common shares. On May 18, 2026, he converted 3,750 restricted stock units into 3,750 shares of common stock at a stated price of $0.00 per share.

The restricted stock units vested on May 18, 2026, one day before the company’s 2026 annual meeting of stockholders held on May 19, 2026. Following this exercise-and-hold transaction, Siegel directly owns 14,750 shares of MacroGenics common stock and no longer holds the vested RSUs as a separate derivative position.

Positive

  • None.

Negative

  • None.
Insider SIEGEL JAY PHILIP
Role null
Type Security Shares Price Value
Exercise Restricted Stock Unit 3,750 $0.00 --
Exercise Common Stock 3,750 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct, null); Common Stock — 14,750 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.
RSUs exercised 3,750 shares Restricted stock units converted into common stock on May 18, 2026
Shares after transaction 14,750 shares Common stock directly owned by Siegel following the exercise
Exercise price $0.00 per share Stated price for the RSU-to-common stock conversion
Transaction date May 18, 2026 Date of RSU vesting and derivative exercise reported on Form 4
RSU balance after 0 units Restricted stock unit holdings reported after the conversion
Restricted Stock Unit financial
"security_title":"Restricted Stock Unit","transaction_date":"2026-05-18"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
derivative security financial
"transaction_code_description":"Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):{"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Annual Meeting of Stockholders regulatory
"one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SIEGEL JAY PHILIP

(Last)(First)(Middle)
9704 MEDICAL CENTER DRIVE

(Street)
ROCKVILLE MARYLAND 20850

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/18/2026M3,750A(1)14,750D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit$0(1)05/18/2026M3,750 (2) (2)Common Stock3,750$00D
Explanation of Responses:
1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
2. The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.
Remarks:
Beth A. Smith, Attorney-in-fact05/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MacroGenics (MGNX) director Jay Philip Siegel report?

Jay Philip Siegel reported exercising 3,750 restricted stock units into 3,750 shares of MacroGenics common stock. This was a derivative exercise, not an open-market purchase or sale, and increased his directly held common stock position reported on the Form 4.

How many MacroGenics (MGNX) shares does Jay Philip Siegel hold after this Form 4?

After the reported transaction, Jay Philip Siegel directly owns 14,750 shares of MacroGenics common stock. This reflects the addition of 3,750 shares received from converting vested restricted stock units, as disclosed in the Form 4 insider filing for May 18, 2026.

What happened to Jay Philip Siegel’s restricted stock units in the MacroGenics (MGNX) filing?

Siegel’s 3,750 restricted stock units vested and were converted into 3,750 shares of MacroGenics common stock. After this derivative exercise, his reported restricted stock unit balance is zero, meaning those RSUs no longer exist as a separate derivative security position.

Was the MacroGenics (MGNX) Form 4 transaction an open-market buy or sell?

The Form 4 shows a derivative exercise, not an open-market buy or sell. Code “M” indicates the conversion of 3,750 restricted stock units into common stock at a stated price of $0.00 per share, with no reported open-market transaction in this filing.

When did Jay Philip Siegel’s MacroGenics (MGNX) restricted stock units vest?

The restricted stock units vested on May 18, 2026. A footnote explains this vesting date was one day prior to MacroGenics’ 2026 Annual Meeting of Stockholders, which occurred on May 19, 2026, triggering the conversion into common shares reported on the Form 4.